Provided by Tiger Fintech (Singapore) Pte. Ltd.

Plus Therapeutics, Inc.

0.6279
+0.085715.81%
Post-market: 0.5651-0.0628-10.00%19:59 EDT
Volume:13.72M
Turnover:8.42M
Market Cap:62.33M
PE:-0.27
High:0.6490
Open:0.6000
Low:0.5839
Close:0.5422
52wk High:2.31
52wk Low:0.1634
Shares:99.26M
Float Shares:60.39M
Volume Ratio:0.99
T/O Rate:22.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3407
EPS(LYR):-1.9544
ROE:-522.50%
ROA:-74.05%
PB:20.54
PE(LYR):-0.32

Loading ...

Plus Therapeutics announces publication of results on 186Re Obisbemeda

TIPRANKS
·
Mar 07

US Stocks Likely To Open Higher After Nasdaq 100 Enters Correction Zone: 'Economic Resilience Provides A Foundation For Market Stabilization,' Says Expert

Benzinga
·
Mar 07

Equity Markets Drop as US Layoffs Surge, Tariff Tumult Persists

MT Newswires Live
·
Mar 07

Sector Update: Health Care Stocks Softer Late Afternoon

MT Newswires Live
·
Mar 07

Equity Markets Fall as US Layoffs Surge in February

MT Newswires Live
·
Mar 07

Top Midday Gainers

MT Newswires Live
·
Mar 07

Sector Update: Health Care Stocks Retreat Thursday Afternoon

MT Newswires Live
·
Mar 07

Plus Therapeutics Gets FDA Orphan Drug Designation for Rhenium Obisbemeda in Lung Cancer; Shares Surge

MT Newswires Live
·
Mar 06

BRIEF-Plus Therapeutics Granted U.S. FDA Orphan Drug Designation For Rhenium (186Re) Obisbemeda

Reuters
·
Mar 06

Plus Therapeutics Announces New Employment Inducement Grants

GlobeNewswire
·
Mar 06

Plus Therapeutics Expects $15 Million in Gross Proceeds From Private Placement of Units; Shares Fall

MT Newswires Live
·
Mar 05

Plus Therapeutics sees $15M in gross proceeds from private placement

TIPRANKS
·
Mar 05

Plus Therapeutics granted orphan designation for lung cancer treatment

TIPRANKS
·
Mar 01

Plus Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview

Reuters
·
Feb 28

Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
Feb 27

Plus Therapeutics appoints Russell Bradley as president, CNSide

TIPRANKS
·
Feb 24

Plus Therapeutics secures $5.7M financing

TIPRANKS
·
Feb 18

Press Release: Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

Dow Jones
·
Feb 18